Geode Capital Management, LLC Seres Therapeutics, Inc. Transaction History

Geode Capital Management, LLC

$1.21 Trillion
Q3 2024

A detailed history of Geode Capital Management, LLC transactions in Seres Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,388,639 shares of MCRB stock, worth $1.19 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,388,639

Previous 1,133,625 22.5%

Holding current value

$1.19 Million

Previous $816,000 61.64%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$0.7 - $1.48 $178,509 - $377,420	255,014 Added 22.5%	1,388,639 $1.32 Million
Q2 2024 Aug 09, 2024	SELL	$0.56 - $1.19 $559,450 - $1.19 Million	-999,018 Reduced 46.84%	1,133,625 $816,000
Q1 2024 May 13, 2024	BUY	$0.75 - $1.56 $28,953 - $60,222	38,604 Added 1.84%	2,132,643 $1.64 Million
Q4 2023 Feb 13, 2024	BUY	$0.93 - $2.15 $99,026 - $228,932	106,480 Added 5.36%	2,094,039 $2.93 Million
Q3 2023 Nov 13, 2023	BUY	$2.33 - $5.07 $61,048 - $132,839	26,201 Added 1.34%	1,987,559 $4.73 Million
Q2 2023 Aug 11, 2023	BUY	$4.67 - $6.55 $1.52 Million - $2.13 Million	325,849 Added 19.92%	1,961,358 $9.39 Million
Q1 2023 May 15, 2023	BUY	$4.95 - $6.09 $223,314 - $274,744	45,114 Added 2.84%	1,635,509 $9.27 Million
Q4 2022 Feb 13, 2023	BUY	$5.09 - $9.05 $427,056 - $759,304	83,901 Added 5.57%	1,590,395 $8.91 Million
Q3 2022 Nov 14, 2022	BUY	$3.5 - $7.2 $1.01 Million - $2.07 Million	287,746 Added 23.61%	1,506,494 $9.67 Million
Q2 2022 Aug 12, 2022	BUY	$2.7 - $7.62 $25,463 - $71,864	9,431 Added 0.78%	1,218,748 $4.18 Million
Q1 2022 May 13, 2022	SELL	$6.3 - $8.84 $176,683 - $247,917	-28,045 Reduced 2.27%	1,209,317 $8.61 Million
Q4 2021 Feb 11, 2022	BUY	$6.02 - $11.43 $1.7 Million - $3.22 Million	282,018 Added 29.52%	1,237,362 $10.3 Million
Q3 2021 Nov 12, 2021	SELL	$5.46 - $22.6 $824,339 - $3.41 Million	-150,978 Reduced 13.65%	955,344 $6.65 Million
Q2 2021 Aug 13, 2021	BUY	$18.46 - $24.36 $2.46 Million - $3.25 Million	133,278 Added 13.7%	1,106,322 $26.4 Million
Q1 2021 May 12, 2021	BUY	$17.66 - $28.92 $1.54 Million - $2.52 Million	86,999 Added 9.82%	973,044 $20 Million
Q4 2020 Feb 12, 2021	BUY	$23.25 - $37.73 $2.02 Million - $3.28 Million	86,911 Added 10.88%	886,045 $21.7 Million
Q3 2020 Nov 13, 2020	BUY	$3.74 - $28.74 $228,188 - $1.75 Million	61,013 Added 8.27%	799,134 $22.6 Million
Q2 2020 Aug 13, 2020	BUY	$3.04 - $6.2 $232,265 - $473,698	76,403 Added 11.55%	738,121 $3.51 Million
Q1 2020 May 14, 2020	BUY	$2.64 - $3.82 $107,667 - $155,791	40,783 Added 6.57%	661,718 $2.36 Million
Q4 2019 Feb 13, 2020	BUY	$2.99 - $4.42 $218,488 - $322,982	73,073 Added 13.34%	620,935 $2.14 Million
Q3 2019 Nov 12, 2019	BUY	$2.29 - $4.16 $198,671 - $360,904	86,756 Added 18.81%	547,862 $2.2 Million
Q2 2019 Aug 14, 2019	BUY	$2.28 - $7.35 $417,579 - $1.35 Million	183,149 Added 65.89%	461,106 $1.48 Million
Q1 2019 May 14, 2019	BUY	$4.83 - $7.21 $194,083 - $289,719	40,183 Added 16.9%	277,957 $1.91 Million
Q4 2018 Feb 13, 2019	BUY	$4.52 - $8.88 $51,871 - $101,906	11,476 Added 5.07%	237,774 $1.07 Million
Q3 2018 Nov 13, 2018	SELL	$7.33 - $9.23 $725 - $913	-99 Reduced 0.04%	226,298 $1.72 Million
Q2 2018 Aug 14, 2018	SELL	$6.91 - $9.55 $7,773 - $10,743	-1,125 Reduced 0.49%	226,397 $1.95 Million
Q1 2018 May 15, 2018	BUY	$7.34 - $11.16 $133,052 - $202,297	18,127 Added 8.66%	227,522 $1.67 Million
Q4 2017 Feb 13, 2018	BUY	$9.15 - $12.64 $348,733 - $481,748	38,113 Added 22.25%	209,395 $2.12 Million
Q3 2017 Nov 14, 2017	BUY	$12.81 - $16.85 $15,205 - $20,000	1,187 Added 0.7%	171,282 $2.75 Million
Q2 2017 Aug 14, 2017	BUY	N/A	170,095	170,095 $1.92 Million

Others Institutions Holding MCRB

# of Institutions

Shares Held

40.5M

Call Options Held

304K

Put Options Held

471K

View Full List

About Seres Therapeutics, Inc.

Ticker MCRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,072,000
Market Cap $107M
Description
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...

More about MCRB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Seres Therapeutics, Inc. Transaction History